ArriVent BioPharma completes IPO of 9.7M shares at $18, raising ~$175M

ArriVent BioPharma, Inc.

IPO of 9,722,222 shares of common stock at $18.00 per share closed January 30, 2024.
Gross proceeds to the company were approximately $175.0 million before expenses.
Amended and restated certificate of incorporation and bylaws filed and effective upon IPO closing.
Common stock trades on Nasdaq under ticker AVBP.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ArriVent BioPharma, Inc.: Amended and restated certificate of incorporation filed in connection with closing of IPO (effective 2024-01-30).

Change: charter amendment
Effective: 2024-01-30

Exact text from the filing

On January 30, 2024, ArriVent BioPharma, Inc. (the “Company”) filed its amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of its initial public offering (the “IPO”) of common stock.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ArriVent BioPharma, Inc.: Adopted amended and restated bylaws in connection with closing of IPO (effective 2024-01-30).

Change: bylaw amendment
Effective: 2024-01-30

Exact text from the filing

The Company also adopted its amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.

View on SEC.gov

188 governance changes filed in the last 30 days. Browse all governance changes →

ArriVent BioPharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-008228

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.